Amphastar Pharmaceuticals Big Money Sentiment Crashed in Q2 2018 touching 1.11

“Big money” Positions

In Q2 2018 Amphastar Pharmaceuticals (NASDAQ:AMPH) big money sentiment decreased to 1.11, according to SEC.gov filings. That’s down -0.34, from 2018Q1’s 1.45. 50 funds opened new and increased holdings, while 45 cut down and sold positions in Amphastar Pharmaceuticals so the sentiment turned negative. These funds own 19.80 million shares, that’s down from 20.28 million shares in 2018Q1. Funds holding Amphastar Pharmaceuticals in top 10 changed to 0 from 0 for the same number . 11 Investors Sold All; 34 Reduced Holdings; 35 increased holdings while 15 funds bought holdings.

Significant Amphastar Pharmaceuticals Shareholders

Cortina Asset Management Llc owns 392,296 shares in Amphastar Pharmaceuticals as of Q2 2018. Amphastar Pharmaceuticals’s shareholder Argent Capital Management Llc owns 235,775 shares as of Q2 2018. Federated Investors Inc Pa reported 1.28 million shares. Rothschild Asset Management Inc revealed 328,841 shares position in Amphastar Pharmaceuticals. The New York-based fund Engineers Gate Manager Lp holds 25,333 shares or 0.03% of their fund’s portfolio.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products.The company has $1.01 billion market cap. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.Currently it has negative earnings. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

The stock increased 1.24% or $0.27 during the last trading session, hitting $21.99.Amphastar Pharmaceuticals, Inc. has 248,433 shares volume, 15.61% up from normal. AMPH is uptrending and has moved 17.25% since December 8, 2017. The stock outperformed the S&P500 by 1.63%.

On March, 11 is anticipated Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s earnings report, as reported by RTT. Last year’s EPS was $0.1, while now analysts expect change of 10.00 % up from current $0.11 EPS. If reported the P/E will be 49.98 with $5.07 million profit. Analysts at Wall Street see Amphastar Pharmaceuticals, Inc.’s -8.33 % negative EPS growth compared to $0.12 EPS for previous quarter.

Moreover, Texas Permanent School Fund has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 23,165 shs. Teachers Retirement Sys Of The State Of Kentucky owns 7,031 shs. Sector Pension Invest Board reported 22,698 shs stake. Sg Americas Secs Limited Liability has invested 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Sei Invests Company has invested 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Bankshares Of Montreal Can reported 0% stake. Parametric Port Assocs Limited Co reported 0% stake. Bluemountain Capital Ltd Liability Corporation has invested 0.01% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). 19,841 were reported by Acadian Asset Ltd Liability Corporation. New York State Common Retirement Fund accumulated 42,720 shs. Ubs Asset Mngmt Americas Inc holds 0% or 297,488 shs in its capital. Ameritas Inv Prtnrs has invested 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Alliancebernstein Lp reported 124,100 shs stake. Jpmorgan Chase & stated it has 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Pinnacle Fincl Partners invested in 1,000 shs.

For more Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news brought out recently go to: Benzinga.com, Nasdaq.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO – Benzinga” brought out on December 04, 2018, “Amphastar Pharmaceuticals (AMPH) Matches Q3 Earnings Estimates – Nasdaq” on November 08, 2018, “BHC or AMPH: Which Is the Better Value Stock Right Now? – Nasdaq” with a publish date: November 22, 2018, “Amphastar Pharmaceuticals’ (AMPH) Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” and the last “Amphastar announces expansion of Amphastar Nanjing Pharmaceuticals Inc. – Seeking Alpha” with publication date: July 09, 2018.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.